Convexia
Uncover drug assets 10x faster with AI-powered sourcing and evaluation
Convexia is an AI-driven drug sourcing and evaluation platform that helps pharma, biotech, and investment groups discover overlooked drug assets globally. It combines specialized AI agents for in silico simulation, market analysis, and operational risk scoring with human expert review at each stage. The platform is also licensing individual modules and running pilots, with a long-term goal of acquiring and developing drug assets independently.
Convexia uses a multi-step pipeline of specialized AI agents — covering asset discovery, in silico evaluation, market analysis, and operational risk scoring — combined with PhD-level human review and KOL roundtables to produce go/no-go decisions on drug assets.
pharma companies, biotech firms, and investment groups seeking drug asset discovery and diligence
Background.
- Status
- launched
- Business model
- subscription
- Company
- Convexia
Similar projects.
Editorial take on the space this project sits in — momentum signals, adjacent moves, our call on whether the wedge is real. Get pinged when we publish a new read or when the landscape shifts.
Have a take on this space?
Tell us what you’d build differently, where you think the incumbents miss, or what we’ve gotten wrong about this project. Comments + reactions are coming soon.